This paper details the use of Sapient's discovery metabolomics method to uncover an early biomarker of HIE.
See how DynamiQ transforms the pace & precision of drug development by grounding every insight in real‑world human biology.
Measure proteins & PTMs directly, at scale – covering 5,400+ proteins in plasma and 12,000+ in tissue matrices.
Gain an unprecedented view into dynamic factors that modulate health, disease pathobiology & drug response.
Measure the proteins that matter most to your study – precisely, quantitatively, and at scale.
How our comprehensive library of 13,000+ reference standards enhances the speed, quality & extent of metabolite identification.
This panel offers highly sensitive multiplexed analysis of 220 biomarkers considered the hallmarks of neurodegenerative diseases.
With AI & large-scale omics datasets more accessible than ever, what does the future hold for biomarker-guided medicine?
We'll be featuring our latest launches in FFPE proteomics, cell surface proteomics, and DynamiQ for oncology R&D.
Mapping pathway‑level mechanisms & molecular drivers behind signatures observed via high-content imaging.
Bridging the gap between genomic target discovery & functional target validation that provides proof of mechanism.
Enabling absolute quantitation of APOE4, BD-pTau217, Aβ42, GFAP, and NfL in a single multiplexed assay.
